Abstract by Spencer Hayes
Chemistry and Biochemistry
Pam Van Ry
Galectin-1 Reduces Inflammation Signaling in Limb-Girdle Muscular Dystrophy Type 2B
Limb-girdle muscular dystrophy type 2B (LGMD2B) is a severe, incurable, debilitating disease where the muscles of major skeletal muscle groups are weakened and atrophied. LGMD2B is caused by mutations in the DYSF gene which encodes for the dysferlin protein. Dysferlin has been found to play a vital role in the cellular membrane repair process within muscle fibers and when mutated or absent, LGMD2B patients experience defective muscle repair leading to inflammation and degeneration of their muscles. Galectin-1 is a naturally occurring 14.5 kDa protein expressed in all parts of the cell within various tissues and is reported to modify immune responses. We show that treatment with galectin-1 lowers inflammation signaling in muscle cells attributing to increased myogenesis and reduced disease pathology. These results illustrate the potential of galectin-1 as a protein therapeutic for LGMD2B.